CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Clinical trial NCT02734862 · COMPLETED

Trial details

NCT number: NCT02734862
Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Candidemia Mycoses Fungal Infection Fungemia Invasive Candidiasis

Start date: 2016-07-26
Primary completion: 2019-06-01
Enrollment: 207

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.